Recent News

Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)

Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update

Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020

Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy

Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock

Athenex, Inc. Announces Proposed Public Offering of Common Stock

Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2+ and HER2- Breast Cancers

Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review

Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update

Our Science

We are focused on discovering and developing novel therapies for treating cancer and addressing unmet medical needs.
Learn more

Investors

View press releases, events and presentations, and other investment information.
Learn more

Join Our Team

As the Company grows, we are always looking to add talented professionals to join the Athenex family.
Learn more

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.
Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.